Acute Coronary Syndrome (ACS) Therapeutics – Pipeline Assessment and Market Forecasts to 2018

Dec. 1, 2011 - PRLog -- GlobalData has estimated that the global ACS therapeutics market valued $6,055.3m in 2005, before increasing at a compounded annual growth rate (CAGR) of 5.8% to reach $8,038.5m in 2010. The market is expected to increase to $8,509.2m by 2018, at a slow CAGR of 0.7%. The slow growth in the forecast period can be attributed to the patent expiries of major marketed products such as Lipitor (atorvastatin), Plavix/Iscover (clopidogrel), Angiomax/Angiox (bivalirudin), Effient/Efient (prasugrel), Integrilin (eptifibatide) and Aggrastat (tirofiban). Patent expiry of major marketed products will attract generic versions of these drugs to the market. However, the expected approval and launch of novel first-in-class therapies such as varespladib from Anthera Pharmaceuticals, darapladib from GSK, dalcetrapib from F. Hoffmann-La Roche Ltd. /Japan tobacco, Xarelto (rivaroxaban) from Bayer, otamixaban from Sanofi, cangrelor from The Medicines Company and elinogrel (PRT128) from Novartis AG/Portola Pharmaceuticals Inc. would offset the impact of these expiries. As these products have a novel mechanism of action compared to currently marketed products, their cost of treatment will be high and, the market penetration of these therapies is anticipated to be slow in initial years. Therefore, the ACS therapeutics market is expected to witness slow growth with a lot of generics playing a major role in the forecasted period, which is similar to the present market scenario.

GlobalData assessed the current ACS therapeutics market to be a weak competitive market. The market is populated by branded drugs, generics and many off-label usage drugs both for the management and treatment of ACS. Although the market has various treatment options, they are moderately successful in meeting the market demand and no single treatment option is able to manage the condition completely. The current treatment options have moderate efficacy and safety profiles. In addition to this, current therapies offer poor quality of life due to their lack of efficacy in reducing cardiovascular events and mortality. As patients only receive treatment through a doctor’s prescription, branded drugs that have a strong market presence dominate sales. At present in the oral platelet aggregation inhibitors class of drugs, Plavix and Aspirin occupy a significant market share. Effient/Efient from Daiichi Sankyo/Eli Lilly is present in the market for unstable angina (UA)/ non-ST-segment elevation and myocardial infarction (NSTEMI) and it received approval with black box warning on its label. However beta blockers, calcium channel blockers, Angiotensin-Converting Enzyme (ACE) inhibitors, antithrombolytics, Angiotensin receptor blockers (ARB’s), statins and nitrates are present in the ACS therapeutics market and these drugs poses a significant market share.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

Three glycoprotein (GP) IIb/IIIa inhibitors on the market at present are Aggrastat, Integrilin and Reopro (abciximab). Out of these, Aggrastat has shown positive long-term results, but Reopro is still clinically relevant in short-term and it is the drug of choice for ACS patients in Percutaneous Coronary Intervention (PCI) settings. However, Aggrastat and Integrilin are less costly compared with Reopro and Integrilin is used more frequently than Aggrastat. These agents are mainly used in patients with recurrent ischemia who are undergoing interventional treatment.

GlobalData, the industry analysis specialist, has released its new report, “Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Acute Coronary Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Acute Coronary Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Coronary Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Acut...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.